Error message

  • Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in include_once() (line 1374 of /kunden/351322_8001/web/5014064/A5014064/
  • Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in menu_set_active_trail() (line 2405 of /kunden/351322_8001/web/5014064/A5014064/

Myopowers Product have been selected for the BIOVISION Investor Conference which will take place in Lyon on April 15 & 16, 2015

Fifty promising life sciences start-ups and projects
selected for April 15 and 16.

The selection committees have identified 25 companies seeking funding for the Investor Conference and 25 innovative projects for the Catalyzer session Lyon, France, March 26, 2015 – BIOVISION, the annual forum on future-oriented research in life sciences organized by the Fondation pour l'Université de Lyon, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer pitching sessions.
The third BIOVISION Catalyzer and Investor Conference sessions continue to engage project sponsors and start-up participation from France and around the world. Between 2013 and 2015, the two sessions respectively received 180 and 200 applications.
Many of the young entrepreneurs previously selected or nominated at BIOVISION have gone on to achieve real success, securing stock market listings, funding and partnership arrangements with major pharmaceutical companies.

Co-organized jointly with France Biotech and Lyonbiopôle, the 2015 Investor Conference will bring together start-ups, growth companies and mid-sized businesses to introduce them to financial and industry partners for a series of pitches, discussions and meetings.

This year the topics will include ’Corporate funding in healthcare‘ and ’Research network:
The 25 innovative businesses selected for the pitching sessions were chosen by a committee including high-level independent venture capital investors (VCs), corporate venture funds (CVCs) and investment banks, and co-chaired by Florent Gros, chief executive of Novartis Venture Fund, and Anne Horgan, a partner at Sofinnova Partners.

Click here for reading the article.